Trademark: 97342302
Word
OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)
Status Date
Tuesday, August 8, 2023
Registration Number
7130293
Registration Date
Tuesday, August 8, 2023
Filing Date
Friday, April 1, 2022
Published for Opposition
Tuesday, May 23, 2023
5 Pharmaceutical preparations for human use comprising monoclonal antibodies for the treatment and prevention of cancer
The mark consists of the term "OPDUALAG" in blue with a curved line over it in light blue and yellow and the term "(NIVOLUMAB AND RELATLIMAB-RMBW)" in blue below it.
The color(s) Blue, Light Blue and Yellow is/are claimed as a feature of the mark.
"NIVOLUMAB AND RELATLIMAB-RMBW"
Aug 8, 2023
Notice Of Registration Confirmation Emailed
Aug 8, 2023
Registered-Principal Register
Aug 2, 2023
Teas Change Of Correspondence Received
Aug 2, 2023
Applicant/Correspondence Changes (Non-Responsive) Entered
Aug 2, 2023
Teas Change Of Owner Address Received
May 23, 2023
Official Gazette Publication Confirmation E-Mailed
May 23, 2023
Published For Opposition
May 3, 2023
Notification Of Notice Of Publication E-Mailed
Apr 17, 2023
Approved For Pub - Principal Register
Apr 17, 2023
Examiner's Amendment Entered
Apr 17, 2023
Notification Of Examiners Amendment E-Mailed
Apr 17, 2023
Examiners Amendment E-Mailed
Apr 17, 2023
Examiners Amendment -Written
Apr 14, 2023
Teas/Email Correspondence Entered
Apr 13, 2023
Correspondence Received In Law Office
Apr 13, 2023
Teas Response To Office Action Received
Oct 14, 2022
Notification Of Non-Final Action E-Mailed
Oct 14, 2022
Non-Final Action E-Mailed
Oct 14, 2022
Non-Final Action Written
Sep 30, 2022
Assigned To Examiner
Apr 7, 2022
Notice Of Design Search Code E-Mailed
Apr 6, 2022
New Application Office Supplied Data Entered
Apr 5, 2022
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
